SGRY
Surgery Partners, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-28/100
Last price
13.57
▲ 0.24 (1.80%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.42
Prev close
13.33
Day high
13.57
Day low
13.22
Volume
892.29K
Market cap
$1.76B
P/E (TTM)
—
52W range
11.41 – 23.44
Day trading desk
Gap from prior close
+0.68%
Prior close 13.33
VWAP
13.42
+1.10% from price
Relative volume
0.73×
Normal
Session range
2.72%
13.22 – 13.58
Position in range
97%
Near session high
ATR (14D)
0.76
5.63% of price
Prior day high
13.50
PDH
Prior day low
13.16
PDL
Bid / ask spread
—
Quote not published
Session volume
1.58M
Avg 2.16M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.94%
-8.9%
1M
-5.96%
-7.1%
3M
-18.73%
-23.2%
6M
+6.09%
-12.1%
YTD
-13.20%
-27.5%
1Y
-36.60%
-53.0%
3Y
-54.15%
-136.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on SGRY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.33M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | DELUCA TERESA Director |
BUY | 10.00K | $143.50K | Direct |
| Aug 18, 26 | DELUCA TERESA Director |
BUY | 11.25K | $161.21K | Direct |
| Jun 18, 26 | HENDRIX BLAIR E Director |
STOCK | 34.36K | $500.00K | Direct |
| Jun 5, 26 | DELUCA TERESA Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | DEANE JOHN A Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | ADLERZ CLIFFORD G Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | HENDRIX BLAIR E Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | TURNER BRENT Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | DEAN LLOYD H Director |
STOCK | 11.67K | $160.00K | Direct |
| Jun 5, 26 | FORESE LAURA L Director |
STOCK | 11.67K | $160.00K | Direct |
| Mar 16, 26 | EVANS JASON ERIC Chief Executive Officer |
SELL | 20.40K | $254.39K | Direct |
| Mar 16, 26 | DOHERTY DAVID T. Chief Financial Officer |
SELL | 8.87K | $110.84K | Direct |
| Mar 13, 26 | BRITTENHAM MARISSA Officer |
SELL | 3.66K | $45.86K | Direct |
| Mar 13, 26 | BURKHALTER DANIELLE Officer |
SELL | 3.47K | $44.51K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BALDOCK JENNIFER BOYD |
Officer | 326.47K | Sale |
BANE HARRISON R |
Officer | 117.18K | Sale |
BRITTENHAM MARISSA |
Officer | 94.20K | Sale |
BURKHALTER DANIELLE |
Officer | 76.86K | Sale |
DEVEYDT WAYNE S |
Officer and Director | 105.20K | Stock Award(Grant) |
DOHERTY DAVID T. |
Chief Financial Officer | 221.68K | Sale |
EVANS JASON ERIC |
Chief Executive Officer | 920.39K | Sale |
OPPENHEIMER JUSTIN ROBERT |
Chief Operating Officer | 120.26K | Stock Award(Grant) |
TURNER BRENT |
Director | 86.59K | Stock Award(Grant) |
WEBB WILLIAM TRENTON |
Officer | 104.35K | Sale |
Fundamentals
Market cap$1.76B
Enterprise value$7.39B
Revenue (TTM)$3.37B
Gross profit$757.90M
EBITDA$646.40M
Net income$-88.60M
EPS (TTM)$-0.69
Free cash flow$183.56M
Total cash$216.70M
Total debt$4.07B
Book value / share$12.88
Shares outstanding130.92M
Float65.77M
Short % of float20.11%
Dividend yield0.00%
Beta (5Y)1.91
Valuation & profitability ratios
Trailing P/E—
Forward P/E47.89
PEG ratio—
Price / sales—
Price / book1.04
EV / revenue2.20
EV / EBITDA11.43
Gross margin22.51%
Operating margin13.72%
Profit margin-2.63%
Return on equity2.32%
Return on assets3.67%
Debt / equity117.26
Current ratio1.95
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.31B | $3.11B | $2.74B | $2.54B | +6.2% |
| Operating revenue | $3.31B | $3.11B | $2.74B | $2.54B | +6.2% |
| Cost of revenue | $2.54B | $2.37B | $2.10B | $1.96B | +7.4% |
| Gross profit | $765.00M | $745.60M | $647.50M | $574.90M | +2.6% |
| Selling, general & admin | $118.20M | $138.70M | $120.90M | $102.20M | -14.8% |
| Total operating expense | $294.20M | $291.30M | $239.00M | $217.00M | +1.0% |
| Operating income | $470.80M | $454.30M | $408.50M | $357.90M | +3.6% |
| Net interest income | -$272.60M | -$201.70M | -$193.00M | -$234.90M | -35.2% |
| Pre-tax income | $116.90M | $147.10M | $135.00M | $110.30M | -20.5% |
| Tax provision | $18.00M | $134.60M | -$300.00K | $23.30M | -86.6% |
| Net income | -$77.90M | -$168.10M | -$11.90M | -$54.60M | +53.7% |
| Net income to common | -$77.90M | -$168.10M | -$11.90M | -$54.60M | +53.7% |
| Basic EPS | -0.61 | -1.33 | -0.09 | -0.59 | +54.1% |
| Diluted EPS | -0.61 | -1.33 | -0.09 | -0.59 | +54.1% |
| EBIT | $389.50M | $348.80M | $328.00M | $345.20M | +11.7% |
| EBITDA | $565.50M | $501.40M | $446.10M | $460.00M | +12.8% |
| Basic shares | 127.21M | 126.12M | 125.61M | 91.95M | +0.9% |
| Diluted shares | 127.21M | 126.12M | 125.61M | 91.95M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $239.90M | $269.50M | $195.90M | $282.90M | -11.0% |
| Cash & short-term investments | $239.90M | $269.50M | $195.90M | $282.90M | -11.0% |
| Accounts receivable | $602.20M | $579.10M | $496.40M | $456.30M | +4.0% |
| Inventory | $96.60M | $88.40M | $75.20M | $71.40M | +9.3% |
| Total current assets | $1.15B | $1.12B | $895.00M | $921.00M | +2.8% |
| Property, plant & equipment | $1.44B | $1.38B | $1.22B | $1.16B | +4.2% |
| Goodwill & intangibles | $5.24B | $5.11B | $4.38B | $4.18B | +2.4% |
| Total assets | $8.12B | $7.89B | $6.88B | $6.68B | +2.9% |
| Total current liabilities | $615.50M | $624.40M | $523.00M | $493.40M | -1.4% |
| Current debt | $99.30M | $101.40M | $73.30M | $62.80M | -2.1% |
| Long-term debt | $3.60B | $3.27B | $2.70B | $2.56B | +10.2% |
| Total debt | $4.02B | $3.70B | $3.06B | $2.93B | +8.7% |
| Total liabilities | $4.59B | $4.25B | $3.51B | $3.40B | +7.9% |
| Retained earnings | -$815.20M | -$737.30M | -$569.20M | -$557.30M | -10.6% |
| Shareholder equity | $1.71B | $1.79B | $1.99B | $2.00B | -4.3% |
| Working capital | $535.20M | $495.00M | $372.00M | $427.60M | +8.1% |
| Net tangible assets | -$3.52B | -$3.32B | -$2.39B | -$2.18B | -6.0% |
| Shares issued | 129.32M | 127.11M | 126.59M | 125.96M | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $98.90M | $12.50M | $135.30M | $87.00M | — | +691.2% |
| Depreciation & amortisation | $176.00M | $152.60M | $118.10M | $114.80M | — | +15.3% |
| Stock-based compensation | $14.80M | $33.30M | $17.70M | $18.40M | — | -55.6% |
| Change in working capital | -$110.40M | -$118.90M | -$63.50M | -$102.30M | — | +7.1% |
| Operating cash flow | $274.30M | $300.10M | $293.80M | $158.80M | — | -8.6% |
| Capital expenditure | -$78.70M | -$90.40M | -$88.80M | -$80.60M | — | +12.9% |
| Investing cash flow | -$246.60M | -$488.50M | -$225.60M | -$307.90M | — | +49.5% |
| Dividends paid | — | — | $0 | $0 | -$5.10M | — |
| Financing cash flow | -$57.30M | $262.00M | -$155.20M | $42.10M | — | -121.9% |
| Free cash flow | $195.60M | $209.70M | $205.00M | $78.20M | — | -6.7% |
| End cash position | $239.90M | $269.50M | $195.90M | $282.90M | — | -11.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $848.90M | $810.90M | $885.00M | $821.50M | $826.20M | +4.7% |
| Operating revenue | $848.90M | $810.90M | $885.00M | $821.50M | $826.20M | +4.7% |
| Cost of revenue | $658.70M | $650.70M | $672.80M | $626.20M | $630.60M | +1.2% |
| Gross profit | $190.20M | $160.20M | $212.20M | $195.30M | $195.60M | +18.7% |
| Selling, general & admin | $36.30M | $39.30M | $23.70M | $22.40M | $36.10M | -7.6% |
| Total operating expense | $73.70M | $76.10M | $87.40M | $60.20M | $74.30M | -3.2% |
| Operating income | $116.50M | $84.10M | $124.80M | $135.10M | $121.30M | +38.5% |
| Net interest income | -$69.80M | -$69.10M | -$67.60M | -$74.90M | -$67.90M | -1.0% |
| Pre-tax income | $32.30M | -$3.30M | $42.60M | $30.80M | $43.80M | +1,078.8% |
| Tax provision | $2.60M | -$1.20M | $13.60M | $5.50M | -$1.10M | +316.7% |
| Net income | -$15.00M | -$35.90M | -$15.00M | -$22.70M | -$2.50M | +58.2% |
| Net income to common | -$15.00M | -$35.90M | -$15.00M | -$22.70M | -$2.50M | +58.2% |
| Basic EPS | -0.12 | -0.28 | -0.12 | -0.18 | -0.02 | +57.1% |
| Diluted EPS | -0.12 | -0.28 | -0.12 | -0.18 | -0.02 | +57.1% |
| EBIT | $102.10M | $65.80M | $110.20M | $105.70M | $111.70M | +55.2% |
| EBITDA | $141.40M | $104.30M | $170.10M | $145.20M | $152.00M | +35.6% |
| Basic shares | 128.82M | 128.37M | 128.03M | 127.21M | 126.98M | +0.4% |
| Diluted shares | 128.82M | 128.37M | 128.03M | 127.21M | 126.98M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $216.70M | $182.30M | $239.90M | $203.40M | $250.10M | +18.9% |
| Cash & short-term investments | $216.70M | $182.30M | $239.90M | $203.40M | $250.10M | +18.9% |
| Accounts receivable | $616.60M | $603.40M | $602.20M | $579.30M | $563.10M | +2.2% |
| Inventory | $98.80M | $100.50M | $96.60M | $92.30M | $87.30M | -1.7% |
| Total current assets | $1.13B | $1.08B | $1.15B | $1.10B | $1.11B | +4.0% |
| Property, plant & equipment | $1.40B | $1.42B | $1.44B | $1.44B | $1.45B | -1.1% |
| Goodwill & intangibles | $5.24B | $5.25B | $5.24B | $5.13B | $5.14B | -0.1% |
| Total assets | $8.05B | $8.04B | $8.12B | $7.95B | $7.95B | +0.1% |
| Total current liabilities | $578.50M | $581.70M | $615.50M | $586.00M | $573.30M | -0.6% |
| Current debt | $102.90M | $100.40M | $99.30M | $103.00M | $110.00M | +2.5% |
| Long-term debt | $3.65B | $3.61B | $3.60B | $3.46B | $3.47B | +1.0% |
| Total debt | $4.06B | $4.03B | $4.02B | $3.87B | $3.88B | +0.7% |
| Total liabilities | $4.58B | $4.56B | $4.59B | $4.39B | $4.38B | +0.4% |
| Retained earnings | -$866.10M | -$851.10M | -$815.20M | -$800.20M | -$777.50M | -1.8% |
| Shareholder equity | $1.67B | $1.69B | $1.71B | $1.73B | $1.75B | -1.0% |
| Working capital | $547.50M | $500.80M | $535.20M | $516.20M | $532.00M | +9.3% |
| Net tangible assets | -$3.57B | -$3.56B | -$3.52B | -$3.41B | -$3.39B | -0.4% |
| Shares issued | 130.89M | 130.80M | 129.32M | 129.02M | 128.21M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $29.70M | -$2.10M | $29.00M | $25.30M | $44.90M | +1,514.3% |
| Depreciation & amortisation | $39.30M | $38.50M | $59.90M | $39.50M | $40.30M | +2.1% |
| Stock-based compensation | $3.80M | $5.80M | -$2.20M | $2.60M | $6.80M | -34.5% |
| Change in working capital | -$28.20M | -$49.60M | -$18.40M | -$18.40M | -$16.70M | +43.1% |
| Operating cash flow | $59.30M | $11.70M | $103.40M | $83.60M | $81.30M | +406.8% |
| Capital expenditure | -$21.80M | -$16.00M | -$12.80M | -$19.80M | -$23.40M | -36.3% |
| Investing cash flow | -$19.80M | -$13.40M | -$126.10M | -$46.20M | $2.10M | -47.8% |
| Financing cash flow | -$5.10M | -$55.90M | $59.20M | -$84.10M | -$62.60M | +90.9% |
| Free cash flow | $37.50M | -$4.30M | $90.60M | $63.80M | $57.90M | +972.1% |
| End cash position | $216.70M | $182.30M | $239.90M | $203.40M | $250.10M | +18.9% |
Options analytics
Put / call volume
0.62
Call-heavy session
Put / call open interest
0.08
Positioning, not flow
Max pain
15.00
+11.9% from spot
ATM implied vol
66.4%
Nearest strike to spot
Skew (10% OTM)
-11.3%
Calls bid over puts
Call volume
13
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
17.50
632 contracts
Heaviest put OI
12.50
44 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.06 | 0.10 | +59.6% |
| Mar 2026 | -0.14 | -0.03 | +77.8% |
| Dec 2025 | 0.30 | 0.12 | -59.7% |
| Sep 2025 | 0.16 | 0.13 | -19.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.12 | 4 | $796.19M | -3.1% |
| Next quarter | 0.14 | 4 | $691.40M | -21.9% |
| Current year | 0.35 | 4 | $3.15B | -4.9% |
| Next year | 0.28 | 4 | $2.81B | -10.7% |
Analyst targets & ownership
Mean target$18.82
High target$24.00
Low target$14.00
Implied upside38.67%
Analyst count11
ConsensusBUY
Strong buy / Buy1 / 8
Hold3
Sell / Strong sell0 / 0
Held by insiders1.80%
Held by institutions121.26%
Institutions holding264
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.94
-2.67% from price
SMA 20
13.99
-4.12% from price
SMA 50
14.44
-7.15% from price
SMA 100
14.71
-7.77% from price
SMA 200
14.50
-7.52% from price
EMA 12
13.80
-1.67% from price
EMA 26
14.03
-3.31% from price
EMA 50
14.31
-5.16% from price
RSI (14)
43.7
Neutral
MACD (12,26,9)
-0.23
Hist -0.08
ATR (14)
0.76
5.70% of price
Realised vol 30D
60.7%
Annualised
Bollinger upper
15.22
20, 2σ
Bollinger lower
12.75
20, 2σ
50 / 200 cross
Death
14.44 vs 14.50
Trend bias
Below 200
-7.52%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.71
Less volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
60.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-49.9%
Peak to trough
Max drawdown 5Y
-81.4%
Peak to trough
ATR 14
0.76
5.70% of price
Beta (reported)
1.91
5Y monthly, from filing
Short interest
Shares short
13.29M
Prior 12.65M
Change vs prior
+5.0%
Shorts adding
% of float
20.11%
Heavily shorted
% of shares out
10.15%
Against total outstanding
Days to cover
5.3
Crowded exit
Float
65.77M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 18, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Sep 14, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Aug 11, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 11, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 11, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Mar 5, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Mar 5, 26 | UBS | MAINTAINED | Buy | Buy |
| Mar 5, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Mar 4, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Mar 3, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Dec 18, 25 | Mizuho | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-17
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-24
Corporate Changes & Voting Matters
8-K · 2026-06-05
Periodic Financial Reports
10-Q · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-23
Periodic Financial Reports
10-K · 2026-03-02
Corporate Changes & Voting Matters
8-K · 2025-12-16
Headlines
Surgery Partners' Idaho Falls Sales Tightens Core Strategy, RBC Says
MT Newswires · 6d ago
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
StockStory · 13d ago
Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · 14d ago
Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?
Zacks · 14d ago
Can Intuitive Surgical Make Up For A Lower Price Per Surgery?
Trefis · 19d ago
Surgery Partners Lowers 2026 Revenue Guidance; Completes $797 Million Sale of Idaho Falls Facilities
MT Newswires · 20d ago
Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction
GlobeNewswire · 20d ago
Surgery Partners Director Teresa DeLuca Buys 11,250 Shares
Motley Fool · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.